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Edited by Vlamidir SkulachevAbstract Friedreich ataxia, the most common autosomal
recessive ataxia, is caused by frataxin deﬁciency. Reduction of
frataxin has been associated with iron accumulation and
sensitivity to iron induced oxidative stress. To better understand
the function of frataxin, transgenic mice (tgFxn) overexpressing
human frataxin were generated. Iron metabolism parameters in
tgFxn were normal and no signs of ataxia or other obvious
abnormalities were observed, indicating that overexpression of
frataxin in mouse is innocuous. Several hypotheses for frataxin
function were evaluated in tgFxn mice. In particular, we
observed that TgFxn mice show an altered response during
hematopoietic diﬀerentiation, suggesting that frataxin may
directly aﬀect heme synthesis.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Friedreich ataxia (FA) is the most common autosomal re-
cessive ataxia in Caucasians, with an estimated prevalence in
this group of 2–4 per 100 000 individuals [1–3]. The major
cause of this disease is the presence of a large (GAA)n repeat
expansion in the ﬁrst intron of the FA gene, FRDA [4]. When
present, this large (GAA)n repeat decreases the transcription
of the mRNA encoding the protein frataxin [5,6] to levels
ranging from 5% to 30% of normal [7].
FA patients develop progressive ataxia around puberty, with
gait ataxia and generalized clumsiness being the most common
initial symptoms [8]. The main pathological changes occur in
the dorsal root ganglia, with loss of large sensory neurons,
degeneration of spinocerebellar tracts, and atrophy of the large
myelinated sensory ﬁbers of peripheral nerves [8]. A hallmark* Corresponding author. Fax: +32-2-555-3942.
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Abbreviations: FA, Friedreich ataxia; tgFxn, transgenic mice overex-
pressing frataxin; DOX, doxorubicin; PHZ, phenylhydrazine; ISC,
iron–sulfur cluster
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doi:10.1016/j.febslet.2004.07.022of the disease is the observed iron accumulation in cardio-
myocytes in FA patients [9].
Frataxin is a nuclear-encoded mitochondrial protein ex-
pressed in every cell type, but its level of expression varies
widely in diﬀerent tissues and during development. Frataxin
mRNA is most abundant in the heart and spinal cord, fol-
lowed by the liver, skeletal muscle, and pancreas [4]. The dis-
tribution of frataxin mRNA in the mouse is in good
accordance with the pattern of distribution observed in adult
human tissues [10,11]. Northern blot and RNA in situ hy-
bridization studies in mouse embryos showed expression
starting at day E10.5, reaching its highest level at day E14.5
and into the postnatal period [10,11]. Embryonic lethality at
day E6.5 of homozygous frataxin knockout mice indicates an
even earlier expression of frataxin, and suggests an important
role during early embryonic development [12].
Although the precise function of frataxin remains unknown,
it has been known now for long now that frataxin in yeast
plays an important role in the maintenance of mitochondrial
iron homeostasis [13–17] and cellular respiration [18,19].
Disruption of the yeast homolog (DYFH1) leads to a 10-fold
increase in mitochondria iron accumulation compared to wild-
type yeast, loss of mitochondrial DNA, and inability to carry
out oxidative phosphorylation [13,16]. Importantly, human
frataxin complements DYFH1, suggesting that frataxin func-
tion is conserved [14]. Further studies showed that frataxin
deﬁciency leads to excessive free radical production in mito-
chondria and dysfunction of iron–sulfur cluster (ISC) con-
taining enzymes (in particular, respiratory complexes I, II and
III, and aconitase) [19]. Frataxin’s speciﬁc function remains,
however, still elusive. An early step of ISC synthesis, which
takes place on the scaﬀold protein Isu1, is greatly enhanced by
frataxin [15]. It has been proposed that frataxin directly binds
iron [16], shielding it from free radicals and making it available
for ISC synthesis. It is unclear whether this postulated chap-
erone function is speciﬁc to ISC synthesis. Data in yeast in-
dicate that, at least in this organism, heme synthesis may also
be stimulated by frataxin, suggesting a more general role in
mitochondrial iron handling [20]. Alternative hypotheses view
frataxin as a stabilizer of a complex including Isu1 and the
nascent ISC [21], as a protein with a primarily antioxidant
function [22], as an activator of the respiratory chain [23].
Cellular and animal models of reduced frataxin expression
have been developed to better understand the precise molec-
ular mechanisms that cause FA and ﬁnd a therapy for thisblished by Elsevier B.V. All rights reserved.
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the eﬀects of frataxin overexpression, which may be relevant
not only for the understanding of its function, but also to
design gene therapy approaches. Some studies were carried out
in cultured cells [23,24]. As for animal models, a transgenic
mouse line carrying a 370 kb yeast artiﬁcial chromosome
containing the human frataxin gene was generated [25]. The
tissue distribution and levels of expression of frataxin from this
transgene resemble those of the endogenous gene, as expected
with a construct containing all elements which are known to
regulate gene expression, including the original human frataxin
promoter, exons, and introns. This transgene also includes an
additional gene and part of two other genes, which might in-
ﬂuence the results of future experiments. More recently, three
independent transgenic mouse lines were generated with the
FRDA gene in an 188-kb bacterial artiﬁcial chromosome ge-
nomic sequence [26]. Three copies of the transgene per diploid
mouse genome were integrated in a single site in each mouse
line. This construct could rescue the embryonic lethality con-
sequent to the disruption of the mouse frataxin gene (Frda).
Also in this model and in all three lines, the relative expression
of the human FRDA and mouse Frda genes showed a similar
pattern in diﬀerent tissues.
For the present study, we generated transgenic mice with
ubiquitous and constitutive overexpression of frataxin by us-
ing an artiﬁcial promoter and frataxin cDNA, which might be
a more realistic gene structure for a potential gene therapy
than the entire gene. Iron metabolism, response to iron chal-
lenge, iron-related oxidative damage, and erythropoietic stress
were all evaluated in this animal model.2. Materials and methods
2.1. Generation of transgenic mice overexpressing frataxin
The Institutional Animal Care Committee reviewed and approved
all procedures, which were performed in accordance with the Canadian
Council on Animal Care guidelines. To generate transgenic mice
overexpressing frataxin (tgFxn), the full-length human frataxin cDNA
was inserted in the EcoRI site of the pCI-neo vector (Promega,
Madison, WI, USA) that carries the human immediate-early enhancer/
promoter cytomegalovirus (CMV) promoter. To prepare the transgene
(MP214), the vector was digested with the enzymes AlwNI and DraIII,
generating an approximately 3-kb fragment. The MP214 transgene was
then microinjected into pronuclei of fertilized mouse oocytes (C57Bl/
6J  C3H), which were then transplanted into foster mothers. Tail
DNA from the resulting 29 oﬀspring was analyzed by Southern blot
and PCR. For Southern blot analysis, 10 lg of DNA was digested with
HinfI, run overnight in a 0.8% agarose gel, and transferred to Hybond-
Nþ nylon membrane (Amersham – Life Science, Arlington Heights,
IL, USA) using standard procedures [27]. After UV cross-linking, blots
were hybridized with the MP214 EcoRI digested fragment that was
labeled by random priming using the Red prime Labeling System
(Amersham Biosciences). Membranes were exposed to X-ray ﬁlm at
)80 C for 24–48 h. For PCR analysis, primers PCI-1206F (50-
GTGGTTTGTCCAAACTCATCAATG-30) and Exon4-939R (50-
CTAGGAACCTATGTGATCAACAAG-30) were used to identify the
presence of the transgene. As an internal control for the PCR, the
endogenous locus Dystonia musculorum (dt) [28] was ampliﬁed using
primers RAS-57 (50-GGCAGCTGTCTTTGCTTCTGTGCACCC-
GAAG-30) and RAS-58 (50-GGGCGCGCTCTGCACCAGCTG-
TTACAGTAC-30). Three transgenic founders were identiﬁed and
backcrossed into the C57Bl/6 background.
2.2. Quantiﬁcation of the number of inserted copies
Genomic DNA (10 lg) from the F1 progeny of transgenic positive
mice was digested with SacI and analyzed by Southern blot. Blots were
hybridized sequentially to a 0.9 kb EcoRI fragment from the MP214transgene and a 1.3 kb SacI fragment from the dt locus [29]. The in-
serted copy number was determined by analyzing autoradiograms with
Scion image software (Scion Corporation, MD, USA). The intensity of
each frataxin band was corrected according to the intensity of the
endogenous dt band.
2.3. Western blot analysis
Tissues were homogenized in 10 volumes of Laemmli buﬀer and
adjusted to a ﬁnal protein concentration of 2 lg/ll, using the Sigma
protein assay following the manufacturer’s protocol (Sigma, St. Louis,
MO); 15 lg of each homogenate was loaded onto a 12% Tris–glycine
SDS–polyacrylamide gel, run by electrophoresis and then blotted onto
a Hybond-C super membrane (Amersham). Blots were probed with a
monoclonal antibody to frataxin (Chemicon, Temecula, CA, USA)
that recognizes both human and mouse frataxin, as well as with a
monoclonal antibody to b-tubulin (Calbiochem, S. Diego, CA, USA)
or to b-actin (Abcam, Cambridge, UK) to control for protein loading.
Speciﬁc signals were visualized by chemiluminescence. Quantiﬁcation
of frataxin expression was determined by analyzing autoradiograms
with Scion image software. The intensity of each frataxin band was
corrected according to the intensity of the b-tubulin (or b-actin) band
for that same lane.
2.4. Transferrin saturation and erythroid parameters
Hemoglobin (Hb), hematocrit (HCT), red blood cells (RBC), and
mean corpuscular volume (MCV) were determined in EDTA-treated
blood samples using an automated blood counter (ABX hematology,
Montpellier, France). Serum iron (SI) and total iron-binding capacity
(TIBC) were measured using a Kodak Ektachem DT60 instrument
(Johnson & Johnson, Clinical Diagnostics, NY, USA). Transferrin
saturation (TS) was calculated from the TIBC and SI values.
2.5. Dietary iron-loading
Dietary iron-loading was achieved by placing six-weeks-old mice on
an iron-enriched diet containing 3% (wt/wt) carbonyl iron (Sigma) for
a period of one month.
2.6. Measurement of tissue iron levels
Organ samples were weighted wet, dried overnight at 106 C and
then weighted again. Dried samples were ashed in an oven at 500 C
for 17 h, solubilized in 6 N HCl, and the ﬁnal solution was adjusted
with demineralized water to a ﬁnal concentration of 1.2 mol/L HCl.
Iron concentration was determined by ﬂame atomic absorption spec-
trometry (AAS).
2.7. Histology
Tissue samples from liver, spleen, heart and pancreas were ﬁxed in
buﬀered 4% formaldehyde and embedded in paraﬃn. Tissue sections
were stained with hematoxylin/eosin and trichrome blue for detection
of ﬁbrosis. Ferric iron (Fe(III)) was detected by Prussian blue staining.
2.8. Doxorubicin treatment
Doxorubicin (DOX) can bind to iron forming a highly reactive
complex that ultimately leads to an increase in oxidative stress. The
major site of iron–DOX interaction has been identiﬁed within mito-
chondria and the heart has been shown to be the organ most severely
aﬀected [30–33]. Since frataxin can possibly act as a detoxifying agent
of reactive-oxygen species [34–36], or as a sequester of iron excess in
the mitochondria [15], the possible protective role of frataxin in DOX-
induced cardiotoxicity was analyzed. Eight-weeks-old tgFxn line #3
and normal controls were injected i.p. with DOX hydrochloride (2 mg/
ml in saline, Sigma) at 25 mg/kg. At day 4, animals were anaesthetized
with 65 mg/kg pentobarbital and blood was collected by cardiac
puncture. Serum creatine kinase (CK) and lactate dehydrogenase
(LDH) activity were determined by colorimetric assay using a Kodak
Ektachem DT60 instrument (Johnson & Johnson).
2.9. Phenylhydrazine treatment
Acute treatment of mice with phenylhydrazine (PHZ) causes he-
molytic anemia, triggering active erythropoiesis in the spleen. In order
to assess whether frataxin expression changes with erythropoiesis in
vivo, wild-type mice were treated with PHZ (i.p. 60 mg/kg body
weight) for two consecutive days. Spleens were collected for protein
extracts and ﬂow cytometry analysis at day 4 and 6 after treatment and
from mice without treatment as controls. In addition, to determinate if
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ulation, ﬂow cytometry was performed on the same samples used to
prepare the protein extracts. Spleens of mice treated with saline were
used as controls. Cell suspensions were obtained by passing the tissue
through a 40 lm ﬁlter followed by centrifugation. Cells were resus-
pended in PBS and stained with anti-rat Ter119 and CD71 mAbs
(PharMingen, San Diego, CA), and analyzed by ﬂow cytometry with a
Coulter Epics (Coulter). The transferrin receptor (CD71), expressed at
high levels in early erythroid precursors, and the cell-surface erythroid-
speciﬁc Ter119 antigen, expressed in terminally diﬀerentiating ery-
throblasts were used to discriminate between the diﬀerent erythroid cell
populations [37]. In the spleen, pro-erythroblasts express high levels of
CD71 and medium levels of Ter119 (CD71high/Ter119med), basophilic
erythroblasts highly express both markers (CD71high/Ter119high), while
late basophilic and polychromatophilic erythroblasts continue to ex-
press high levels of Ter119 but show a reduction on CD71 expression
(CD71med/Ter119high) [37].
Additionally, response to hemolytic anemia of transgenic mice as
well wild-type mice was determined by hematological parameters.
Eight-weeks-old tgFxn lines #1 and #2, and normal controls were
injected i.p. with 6 mg/Kg PHZ (total of 60 mg/kg body weight/day,
Sigma), for two consecutive days. Blood was collected for hemato-
logical analyses at day 4, 6 and 11.
2.10. Statistical analysis
Results are presented as means S.D. or means S.E.M., as indi-
cated. Student’s t test was used for comparison between the control
and knockout mouse groups and between treatments. The level of
signiﬁcance was pre-set at P ¼ 0:05.3. Results
3.1. Generation of tgFxn mice
TgFxn mice were generated by introducing full-length hu-
man frataxin cDNA, encompassing exons 1–5a, into the
EcoRI cloning site of the PCI-neo vector (Fig. 1(a)). This
vector contains the CMV promoter, which drives constitutive
expression of cloned DNA inserts in mammalian cells. Out of
the 29 oﬀspring born after microinjection, 5 were positive for
the insertion of the transgene, as determined by Southern
blotting (Fig. 1(b)) and PCR analysis (Fig. 1(c)). Germ line
transmission was observed in 3 independent mouse lines (re-
ferred as tgFxn lines #1, #2, and #3). The number of copiesFig. 1. (a) Structure of the MP214 construct. Arrows represent primers Exon4
SacI restriction sites, used to determine the inserted copy number by Souther
Southern blot analysis. (b) Identiﬁcation of mice carrying the human frataxin
Lanes 1, 3, and 4 are transgenic mice (tgFxnþ=); lanes 2 and 5 are wild-type l
positive mice show a band of 568 bp (lanes 1, 2, 4 and 5). The 300 bp band
endogenous dt locus. Lane 3 is a wild-type littermate.inserted was variable among the diﬀerent lines, ranging from 1
to 6 (Fig. 2). Each generation of tgFxn mice has reproduced
eﬀectively to give normal-sized litters.
3.2. Protein levels and motor coordination in tgFxn mice
Frataxin protein levels were estimated by Western blot
analysis in the heart, brain, pancreas, skeletal muscle, spleen,
kidney, lung and liver. In these experiments, the transgene-
encoded human frataxin band overlaps the endogenous mouse
frataxin band, also recognized by the antibody, so the levels of
transgene expression had to be estimated by comparison with
wild-type, non-transgenic animals. Not unexpectedly, each line
showed a diﬀerent pattern of frataxin overexpression, which is
likely to be related to position eﬀects consequent to the ran-
dom insertion of copies of the transgene in the mouse genome.
However, with the exception of brain in line 2, increased fra-
taxin expression could be obtained in all organs where mouse
frataxin mRNA is normally more abundant [10,11], such as
heart, brain, muscle and pancreas (Fig. 3). These are the or-
gans aﬀected in FA patients and therefore represent targets for
gene replacement therapy.
In order to determine whether overexpression of frataxin
would aﬀect motor coordination and balance in mice, rotarod
analysis was performed. Similar performance on the rotarod
was observed in wild-type and in tgFxn mice up to one-year of
age (data not show), well above the corresponding age of onset
in humans (one-year-old mouse is comparable in terms of age
to a 40–50-years-old human). These results indicate that in-
creased frataxin levels are not associated with any obvious
neurological phenotype, at least up to the age studied.
3.3. Iron metabolism in tgFxn mice
In order to study the eﬀect of frataxin overexpression on
iron metabolism, several hematological and iron parameters
were analyzed. Values of Hb, HCT, red blood cells, and MCV
were all within the normal range in tgFxn mice compared with
wild-type mice (Table 1). Levels of SI and TS were also de-
termined, and similar values were found in transgenic mice and
in their wild-type littermates (Table 1). Similar levels of tissue-939F and PCI1206R, used for PCR genotyping. Arrowheads represent
n blot. The bracketed area represents the fragment used as a probe for
transgene, by Southern blot analysis of HinfI digested genomic DNA.
ittermates. (c) PCR analysis of the tgFxnþ= oﬀspring. Only transgenic
is a control band for the PCR, resulting from the ampliﬁcation of the
Fig. 3. Frataxin levels are increased in frataxin tgFxnþ= mice. (a) Heart; (b) brain; (c) muscle and (d) pancreas. Crude protein extracts were probed
with antibodies to frataxin and b-tubulin. WT, wild-type; 1, transgenic line #1; 2 transgenic line #2; 3, transgenic line #3. (e) Quantiﬁcation of
frataxin expression levels.
Fig. 2. Quantiﬁcation of inserted copy number in tgFxnþ= mice: Southern blot analysis of genomic DNA, digested with SacI and probed with
human frataxin cDNA (upper blot). Quantiﬁcation of endogenous D. musculorum was used as control (lower blot). WT, wild-type; 1, transgenic line
#1; 2, transgenic line #2; 3, transgenic line #3. The inserted copy number was obtained after comparing the intensity of each frataxin band and
correcting according to the intensity of the control endogenous band.
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type and tgFxnþ= mice (Table 2). Histological analysis did
not reveal iron or collagen deposition in any of the examined
organs (data not shown).
Next, the response of tgFxnþ= mice to iron challenge was
studied. Six-weeks-old tgFxnþ= mice were placed on a 3%
(wt/wt) carbonyl-iron-supplementation diet for a period of
one month. Analysis of tissue iron concentration clearlyshows that iron loading was achieved in both animal groups.
When comparing mice on a regular diet to mice receiving the
iron-supplemented diet, both tgFxnþ= and wild-type mice
showed a statistically signiﬁcant increase in iron concentra-
tion in all organs with the exception of the heart (Table 2).
Taken together, these results demonstrate that higher frataxin
levels in diﬀerent organs do not alter systemic iron metabo-
lism in mice.
Table 2
Eﬀects of iron-challenge on tissue iron concentration
Mice Treatment n Liver Spleen Heart Pancreas
lg Fe/g dry weight
Wild-type – 13 203 50 1028 294 327 30 75 12
tgFxn, line #1 – 8 197 34 913 236 346 42 79 5
tgFxn, line #2 – 5 215 45 630 145 360 20 79 14
tgFxn, line #3 – 8 189 28 1247 387 379 40 74 11
Wild-type CI 6 842 144 2840 867 333 11 149 43
tgFxn, line #1 CI 7 703 159 2412 837 322 45 121 23
tgFxn, line #2 CI 6 758 166 2412 386 355 45 129 16
tgFxn, line #3 CI 4 1301 194 2887 927 319 9 146 22
CI, carbonyl-iron-supplemented diet. Data are presented as means S.D. n, number of animals. Mice were three-months-old.
* P < 0:05 compared with wild-type.
** P < 0:01 compared with wild-type.
Table 1
Erythroid parameters, SI and TS
Mouse n Hb (g/L) MCV (ﬂ) HCT (%) RBC (1012/L) SI (lmol/L) TS (%)
Wild-type 13 134 22 47 2 43 6 9.1 1.3 23 8 42 14
tgFxn, line #1 8 136 19 45 1 41 6 9.0 1.3 25 5 50 11
tgFxn, line #2 5 114 23 45 1 38 7 8.4 1.4 17 3 41 5
tgFxn, line #3 5 133 8 49 3 43 3 8.7 0.3 23 3 38 7
Data are presented as meansSD. n, number of animals; Hb, hemoglobin; MCV, mean corpuscular volume; HCT, hematocrit; RBC, red blood
cells; SI, serum iron; TS, transferrin saturation. Mice were all three-months-old.
* P < 0:05 compared with wild-type.
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Transgenic mice from line #3 (with the highest levels of
frataxin in the heart) and wild-type mice were treated i.p. with
5 mg/kg of DOX (total dose of 25 mg/kg body weight). Four
days after treatment, levels of serum CK and LDH, both
markers for heart and skeletal muscle damage, were measured.
DOX treatment signiﬁcantly increased serum levels of CK and
LDH, demonstrating muscle damage both in tgFxnþ= and
wild-type mice (Fig. 4); however, similar levels of serum CK
and LDH were found in tgFxnþ= and wild-type mice treated
with DOX (Fig. 4). These results show that overexpression of
frataxin does not protect from the cardiotoxicity induced by
DOX treatment.LDH
*
*
ns16000
0
4000
8000
12000
WT tgFxn #3 WT tgFxn #3
U/
L
Saline DOX
Fig. 4. DOX-induced increase in LDH and CK activity. While DOX induced
injected mice, no diﬀerence was observed in the response of wild-type and tgF
(DOX), wild-type mice injected with 25 mg/kg body weight of DOX; TG (s
(DOX), transgenic mice from line 3 injected with DOX. Values represent mea
used for comparison between saline and DOX treated mice (P < 0:05). ns,3.5. Erythropoietic stress in tgFxnþ= mice
Treatment with PHZ resulted in a dramatic increase in
spleen size (up to 6 times, data not shown), accompanied by
an increased number of all cells from the erythroid lineage
(Table 3). Protein extracts obtained from wild-type mice
treated with PHZ (n ¼ 2 per time point) showed a variable
frataxin expression at day 4, followed by a 6-fold increase at
day 6 (Fig. 5(b)). Flow cytometry analysis of spleen cellular
extracts from mice treated with PHZ showed an increase in
cell populations expressing CD71 or Ter119. Modest increase
was observed in cells expressing CD71med or low/Ter119high (4-
fold at day 6) and cells expressing CD71high/Ter119med or low
(9-fold at day 6), and a remarkable increase in CD71high/CK
tgFxn #3
ns
*
*
2000
tgFxn #3
1600
1200
U/
L
800
400
0
WT WT
DOXSaline
a statistically signiﬁcant increase of both enzymes compared to saline-
xn mice. WT (saline), wild-type mice injected with saline solution; WT
aline), transgenic mice from line #3 injected with saline solution; TG
nsS.E.M. from 8 mice for each treatment group. Student’s t test was
Not signiﬁcant.
Fig. 5. Eﬀect of PHZ treatment on frataxin levels and erythroid diﬀerentiation in the spleen of wild-type mice. (a) Flow cytometry assessment of
spleen erythroid diﬀerentiation. PHZ treatment causes an increase in proerythroblasts (CD71high/Ter119med, blue), erythroblasts (CD71high/
Ter119high, yellow) and reticulocytes/erythrocytes (CD71med/Ter119high, red ). (b) Western blot analysis of frataxin expression in the spleen of wild-
type mice treated with PHZ. After PHZ treatment, frataxin levels increased at day 6. Frataxin expression at day 0 was normalized to 100% and used
as a baseline for all comparisons. Actin was used as a loading control.
Table 3
Frataxin expression and erythroid diﬀerentiation in the spleen of wild-type mice, after treatment with PHZ
Day Mouse # (%)
Frataxin CD71neg/ CD71pos/ CD71pos/ CD71neg/
expression Ter119neg Ter119neg Ter119 pos Ter1119pos
D0 1 100 93.8 4.1 0.1 1.9
2 100 93.7 2.2 0.1 4.0
D4 3 50 86.7 1.4 2.4 9.5
4 200 64.6 4.0 17.8 13.8
D6 5 600 40.4 23.3 28.3 8.0
6 700 28.2 32.6 25.3 13.9
286 C.J. Miranda et al. / FEBS Letters 572 (2004) 281–288Ter119high (250-fold at day 6), corresponding to basophilic
erythroblast cells (Fig. 5(a), Table 3). When the data from
Western blotting were reviewed according to the ﬂow cy-
tometry analysis, the increase in frataxin expression after PHZ
treatment, as clearly seen by day 6, was lower than expected,
if the dramatic increases CD71highTer119high cells would be
taken in account. Western blot analysis revealed only a 6- to
7-fold increase in frataxin expression, at day 6, as compared
to the 250-folds increase expected given the size of the
CD71high/Ter119high cell population (Fig. 5(b), Table 3). The
downregulation of frataxin expression during erythropoiesis
was particularly evident in one wild-type mouse at day 4
(mouse #3), when Western blot analysis showed a 2-fold de-
crease in frataxin expression (Fig. 5(b)), while CD71high/
Ter119high cells increased 24-fold (data not shown). These
results are therefore in agreement with previously published
observations using our in vivo system.Additionally, PHZ was administered to wild-type and
tgFxnþ= mice (lines 1 and 2) and blood samples were col-
lected at days 4, 6 and 11 for hematological analysis (Fig. 6).
Diﬀerent values of Hb and RBC counts were observed in
tgFxn and wild-type mice, at days 4 and 6 after PHZ treat-
ment, reaching statistical signiﬁcance at day 4. These results
showed an initially delayed response of tgFxn mice to PHZ
treatment, although by the end of the time points both wild-
type and tgFxn were shown to recover from PHZ treatment,
with Hb and RBC levels reaching values similar to pre-treat-
ment levels.4. Discussion
Up to this date several attempts have been made to ﬁnd an
eﬃcient therapy for FA, a lethal and very disabling disorder.
a Hb
250
*
*
g/
L 15
0
50
100
0
200
*
D4 D11No PHZ D6
b RBC
10
0
2
4
6
8
No PHZ D4 D6 D11
*
*
X1
01
2  
/L
Wild type tgFxn #1 tgFxn #2
Fig. 6. Frataxin overexpressing mice have a slower recovery from
erythropoietic stress. Alteration in wild-type, tgFxn line 1 and tgFxn
line 2 mice of (a) hemoglobin and (b) RBC counts, after PHZ treat-
ment. TgFxn mice show an altered response to PHZ treatment, as
observed by a delayed response normalization of the hematological
parameters. 6–7-weeks-old animals were used. Data are presented as
means ± S.E.M. (P < 0:05).
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shown a positive impact on cardiac hypertrophy in the ma-
jority of patients, although with no improvement in the neu-
rological condition [38–41]. A combined therapy involving
long term treatment with high doses of vitamin E and coen-
zyme Q10 has shown rapid and sustained increase in the en-
ergy generated by the heart and skeletal muscle [42]. However,
although signiﬁcant, this improvement corresponded only to a
partial amelioration of symptoms. Clearly, more eﬀective drug
treatments are needed.
Since FA results from a reduction of frataxin levels, with
patients having 5–30% of control levels [7], boosting its ex-
pression through gene therapy may be another option. In this
work, we generated mice that overexpress frataxin primarily as
additional tools to study its function, but also as a way to
check whether such overexpression can be toxic, a case that
would aﬀect the design of gene replacement therapy. We ob-
tained three lines of transgenic mice showing high levels of
frataxin in all major organs aﬀected in FA, including pancreas,
brain, skeletal muscle and heart. The speciﬁc pattern of ex-
pression was diﬀerent in each line, likely reﬂecting position
eﬀects related to the sites of insertion of the transgene.
TgFxnþ= mice are born healthy and have no obvious be-
havioral, neurological, metabolic or pathological phenotype
up to the age of one year. Therefore, a ﬁrst conclusion of our
study is that overexpression of frataxin does not have toxic
eﬀects, suggesting that this need not be a concern when de-
signing a gene therapy treatment for FA.Overexpression of frataxin does not seem to grossly aﬀect
iron metabolism, that is normal in all three transgenic lines as
assessed by erythroid parameters analysis, SI levels and TS.
Tissue iron concentration is similar in tgFxnþ= and in wild-
type mice when kept on a standard diet, as well as after iron
loading with a 3% carbonyl-iron supplemented diet for one
month.
We then wished to use these models to further investigate
frataxin function, in particular the hypothesis that it might
prevent oxidative stress [43,44,34]. In a ﬁrst experiment, we
compared TgFxn and wild-type mice for their vulnerability to
DOX toxicity. DOX is a very eﬀective antibiotic used to treat a
large variety of tumors, but whose clinical application has been
limited by the development of dose-dependent cardiotoxicity.
Iron is believed to play a major role in the development of
DOX-induced cardiotoxicity [30,31,33]. Excess iron in the
heart leads to increased susceptibility to DOX-induced car-
diotoxicity, as observed in He-deﬁcient mice [32], and can be
attenuated by the use of iron chelators [45], or by the over-
expression of antioxidant enzymes [46–49]. Since mitochondria
have been identiﬁed as the major site of iron–DOX interaction,
if frataxin exerts an antioxidant function in this compartment
and can prevent iron-mediated free radical formation, it may
be protective against DOX toxicity. However, TgFxn and
wild-type mice show similar susceptibility to DOX toxicity,
indicating that any antioxidant property of frataxin does not
aﬀect the pathway activated by DOX.
We performed a second experiment to test whether frataxin
may be directly involved inmitochondrial ironmetabolism. The
ﬁnal step of heme synthesis, i.e., the insertion of ferrous iron
into the protoporphyrin IX ring, takes place in mitochondria
and is catalyzed by the enzyme ferrochelatase. Though heme
biosynthesis and development of blood, bone marrow and red
cells appear to be grossly normal in patients with FA [50],
frataxin mRNA and protein levels have been shown to decrease
during erythroid development, suggesting that frataxin down-
regulation may promote heme biosynthesis [51]. Constitutive
overexpression of frataxin could therefore interfere with heme
biosynthesis. In our experiment, we conﬁrmed a decrease of
frataxin expression during the erythropoietic response triggered
by PHZ-induced hemolytic anemia and also detected a delayed
response of TgFxn mice compared to wild-type mice. Taken
together, these results suggest a direct involvement of frataxin
in mitochondrial iron metabolism that may not be limited to
ISC synthesis and that deserves further study.
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